Breast cancer is the most common nonskin cancer and the second leading cause of cancer death in U.S. women. Although mammography is the most effective modality for breast cancer screening, it has several potential risks, including high falsepositive rates. Therefore, the balance of benefits and risks, which depend on personal characteristics, is critical in designing a mammography screening schedule. In contrast to prior research and existing guidelines that consider population-based screening recommendations, we propose a personalized mammography screening policy based on the prior screening history and personal risk characteristics of women. We formulate a finite-horizon, partially observable Markov decision process (POMDP) model for this problem. Our POMDP model incorporates two methods of detection (self or screen), age-specific unobservable disease progression, and age-specific mammography test characteristics. We solve this POMDP optimally after setting transition probabilities to values estimated from a validated microsimulation model. Additional published data is used to specify other model inputs such as sensitivity and specificity of test results. Our results show that our proposed personalized screening schedules outperform the existing guidelines with respect to the total expected quality-adjusted life years, while significantly decreasing the number of mammograms and false-positives. We also report the lifetime risk of developing undetected invasive cancer associated with each screening scenario.
Introduction
For years, mammograms have been recommended every year or two for women beginning at age 40. The new report from the US Preventive Services Task Force, issued Monday night, now says women this age should simply talk to their doctors about the benefits and risks.
(USA Today 2009).
Breast cancer is the most common cancer among U.S. women, resulting in more lost years of potential life than any other cancer because of its higher occurrence in younger ages than most cancers (American Cancer Society (ACS) 2009). About one in eight U.S. women will develop breast cancer in their lifetime. In 2009 alone, an estimated 254,650 women were diagnosed with breast cancer and 40,170 died from this disease, making it the second leading cause of cancer deaths in U.S. women (ACS 2009 ). Although there is no guaranteed way to prevent breast cancer, when detected early the disease is more likely to be curable. For example, the five-year survival rate increases from 27% to 98% when breast cancer is detected at early stages compared with later stages (ACS 2009) .
Mammography is the most commonly used, and the only proven, screening modality to detect preclinical breast cancers. On average, mammography detects cancer 1.7 years before a woman can feel the lump and several years before physical symptoms develop (Centers for Disease Control and Prevention (CDC) 1995). The evidence suggests that mammography has a potential to reduce breast cancer mortality rates by 20%-30% (Kerlikowske et al. 1995) . Being fast, reasonably accurate, and widely available make mammography the gold standard for screening.
Nevertheless, mammography is not perfect and has several potential risks, including radiation exposure, pain, overdiagnosis (finding cases that would not have clinically 1020 Operations Research 60(5), pp. 1019 -1034 , © 2012 surfaced and caused breast cancer mortality in a woman's lifetime), and risks associated with false-positive mammograms, i.e., mammograms with positive outcome when the disease is absent (Brewer et al. 2007 ). In particular, false-positive mammograms are serious and harmful because they may lead to unnecessary diagnostic follow-up (e.g., additional imaging and invasive procedures such as biopsy), which may in turn result in associated morbidities, psychological distress including anxiety and depression, considerable amount of time loss, and, as a result, a significant reduction in quality of life (Brewer et al. 2007 ). Yet, false-positive mammograms are not rare (10.7% per mammogram), and the risk increases with increased screening frequency. For every 1,000 healthy women who undergo annual mammograms, more than half will have a false positive, and nearly 200 of them will undergo an unnecessary biopsy within 10 years (Elmore et al. 1998) .
The balance of these health benefits and potential risks is therefore critical for designing an effective mammography screening program. The balance may shift based on certain personal risk characteristics such as age, family history, and parity (Armstrong et al. 2007 ). For example, the benefits and risks of mammography screening differ in younger versus older women, leading to controversy among researchers. Some recommend more-frequent screening for younger women and less-frequent screening for older women because breast cancer is thought to be more aggressive in younger women (Jayasinghe et al. 2005) . In addition, older women are more likely to suffer from risky comorbidities (other health problems increasing the mortality risk such as stroke, hypertension, and myocardial infarction), whereas younger women mostly do not have Table 1 .
Recommended mammography screening policies by various institutions in the United States (Qaseem et al. 2007 , USPSTF 2009 ) and other countries with organized population-based cancer-screening programmes (Klabunde and Ballard-Barbash 2007, Shapiro et al. 1998 such risks (Satariano and Silliman 2003) . On the other hand, there are also reasons to believe that more-frequent screening is beneficial for older women. For example, the incidence and mortality of breast cancer increase dramatically with age (ACS 2009) . Approximately 50% of all newly diagnosed breast cancers occur in women aged 65 years and older (Holmes and Muss 2003) . Furthermore, the accuracy of mammography screening is higher in older women, primarily due to differences in breast densities among older and younger women (Kerlikowske et al. 2000) . These controversies are also reflected in screening guidelines by several major health organizations in the United States and other countries. Significant variations exist among different screening guidelines in terms of the recommended age to start and end mammography screening, as well as the frequency of screening (Table 1) . Recently, the U.S. Preventive Services Task Force (USPTF), a government-appointed expert panel whose stance influences coverage of screening tests by Medicare and many insurance companies, has updated its recommendations from annual to biennial screening between ages 50-74 (USPSTF 2009). Several advocacy groups welcomed the new guidelines, whereas others, including the ACS, disagreed with it (New York Times 2009).
None of these general population-based guidelines consider risk factors other than age. However, evidence suggests that other personal risk factors may also be important for balancing the benefits and risks of a cancer-screening strategy (Armstrong et al. 2007) . As noted by Gail and Rimer (1998) , "the ideal screening recommendation would be one that reflected each woman's individual risks," which is influenced by several other personal characteristics such 1021 as family history, breast density, body mass index (BMI), alcohol consumption, parity, extent of breastfeeding, and ages at menarche, menopause, and first birth. For example, a woman with a family history of breast cancer is two to three times more likely to develop breast cancer compared with a woman who has no family history (Gilbar 1998) .
Understanding that women at the same age groups do not have uniform breast cancer risks suggests that screening strategies that are tailored to individual risks may be more beneficial in increasing life-savings in high-risk women while decreasing unnecessary complications in low-risk women (IOM 2005) . In fact, personalized mammographyscreening strategies are identified in the 2005 Institute of Medicine (IOM) report as "crucial to improving the early detection of breast cancer" (IOM 2005) .
Despite the growing need for tailored screening, a review of the literature indicates that no analytical framework yet exists to plan for personalized screening. The purpose of this study is to begin to address this need. We develop a modeling framework to determine an optimal personalized mammography-screening strategy that accounts not only for static risk factors such as race, age at menarche, and age at first live birth, but also for dynamic risk factors including age and prior screening history (Other dynamic risk factors such as BMI and a changing family history can only be approximately accounted for by redoing the model computations when the change occurs, as we discuss in our concluding section).
We model this problem using a partially observable Markov decision process (POMDP), which is a generalization of a Markov decision process that allows sequential decision making when the information regarding the true state of the system is incomplete. POMDPs allow capturing partial observability of the disease progression and imperfect test results, making them ideally suited to health-care problems. However, the application of POMDPs to medical decision making has been limited to only a few studies, primarily due to their high computational complexity (Schaefer et al. 2004) .
To the best of our knowledge, this is the first analytical study that considers how to personalize mammographyscreening policies. The only study we are aware of that suggests risk-based recommendations for mammography screening is by Gail and Rimer (1998) , which proposes to screen for women between age 40-49 only if the woman's risk at this age equals or exceeds that of the one at 50-years old who has no risk factors for breast cancer. For women over age 50, Gail and Rimer assume that annual screening is optimal. Several other studies investigate populationbased breast cancer screening policies using simulation and analytical models (see Alagoz et al. 2011 for an extensive review). Among these population-based analyses, the most relevant analytical study to ours is by Maillart et al. (2008) , which builds a partially observable Markov chain and provides an upper bound on lifetime breast cancer mortality risk by evaluating numerous alternative screening scenarios. Another relevant study is by Ivy (2002) , which uses a POMDP structure for finding a cost-effective method for mammography screening with respect to the competing objectives of payers and patients. She approximately solves this POMDP assuming that death probabilities and test accuracies are age independent.
Our contributions in this research are twofold: From the application viewpoint, (1) rather than a populationbased policy, we propose a personalized optimal screening strategy that considers several personal risk characteristics of women, including prior screening history; (2) we utilize a validated microsimulation model, which is used also to develop actual policy recommendations, to specify our transition probability parameters; (3) unlike most of the analytical models, we incorporate the possibility of self-detection into the mammography-screening problem; and (4) we acknowledge that disease progression, mortality rates, and test accuracies are age dependent. From the theory viewpoint, (1) we build a POMDP model that is different than conventional POMDP models and better suited to many medical decision-making problems; (2) contrary to prior POMDP applications for real-life problems in the literature, we solve our POMDP optimally; and (3) we derive several structural properties of our POMDP model, which is rarely done in the literature. The assumptions needed to invoke these results at a particular time step depend on the computed parameters from a prior time step. Therefore, it is not possible to use these results to predict a controllimit policy prior to beginning computation. Nevertheless, we feel that these results are still important as they provide useful insights about the overall problem.
The remainder of this paper is organized as follows. In §2, we present the POMDP model for this problem. In §3, we describe the model inputs and parameter estimations. In §4, we present and discuss computational results. Finally, we summarize our findings and conclude in §5. An electronic companion to this paper is available as part of the online version that can be found at http://-dx.doi.org/ 10.1287/opre.1110.1019.
Model Formulation
We formulate a discrete-time, finite-horizon POMDP model to solve this problem, in which a single decision maker such as a patient and/or a physician aims to maximize the total expected quality-adjusted life years (QALYs) of the patient. We assume that the decision maker is risk neutral. Like most of the existing breast cancer screening guidelines (USPSTF 2009), we do not consider the financial costs associated with breast cancer screening in this study because we take the patient's perspective, and these costs are covered by private insurance plans and Medicaid in almost all states (Rathore et al. 2000) .
At the beginning of every six months, a woman either undergoes a mammogram or is recommended to wait for Operations Research 60(5), pp. 1019 -1034 , © 2012 another six months. This decision is made based on the woman's current risk of breast cancer, which may depend on several personal risk factors as well as prior screening history and can be estimated using one of the methods explained in §3.3. If the woman is recommended to have a mammogram and if the mammogram turns out to be positive, it is followed by a perfect follow-up test (e.g., biopsy). This is a reasonable assumption because the literature reports that biopsy is a reliable procedure with true positive rates very close to 1 (Parker et al. 1994) . If the result of the biopsy is also positive (i.e., the woman has cancer), we assume that the woman starts treatment and quits the decision process by moving to a postcancer state with probability 1. This assumption is in line with the existing literature, because the current screening guidelines suggest that women with a personal history of breast cancer have different biologies; therefore, they should not follow the general screening guidelines, but instead they should be screened more aggressively (ACS 2009 ). On the other hand, the woman continues the decision process after a negative mammogram, a negative biopsy following a positive mammogram, or a recommended Wait action. If the woman is recommended to wait for six months, breast cancer may be detected at any time during this period through selfdetection, i.e., either through clinical breast exam (CBE) or breast self-exam (BSE) (Figure 2) . Throughout the paper, we refer to the woman as the "patient," irrespective of her health condition, for consistency. The notation used in the model is as follows.
• t: Decision epochs, t = 0 1 2 T T < . We assume that screening decisions are made every six months and define t as the number of half years above the age 40 (e.g., t = 0 represents age 40, t = 1 represents age 40.5, etc.). The decision epochs start at age 40 because this is the earliest age among the recommended starting ages for routine mammography screening (Qaseem et al. 2007 ). We end our decision horizon at age 100 (i.e., T = 120), consistent with the U.S. life tables reported by the CDC (Arias 2006) .
• S: Core state space, S = 0 1 2 3 4 5 , where s t ∈ S represents the true health state of the patient at time t. In particular, 0 represents a cancer-free patient, 1 represents a patient with in situ (noninvasive) cancer, 2 represents a patient with invasive cancer, 3 represents a patient under in situ cancer treatment, 4 represents a patient under invasive cancer treatment, and 5 represents death. Note that the decision maker directly observes whether the patient is in state 3, or in state 4, or in state 5. However, the decision maker only observes the patient is in one of 0 1 2 , but not which one (Figure 1 ). We separate in situ and invasive cancers in our analysis because risk factors and management for these cancers differ; thus, the benefit of mammography may be different for each cancer type (Reinier et al. 2007 ).
• S : Information space, the space of all probability distributions over the state space S. Any element of S is referred to as an information state, denoted by , which consists of occupation probabilities over the state space. State transition diagram of the underlying Markov process.
In situ cancer
In situ postcancer
That is, if we let s denote the probability of occupying state s, then = s .
• B S P O : Belief space. Any element of B S P O is referred to as a belief state, denoted by b, which is a truncated version of over the partially observable states. For example, if = 0 7 0 2 0 1 0 0 0 , then b = 0 7 0 2 0 1 . Intuitively, b represents the belief of the decision maker about the patient's partially observable health states and is known to be a sufficient statistic for the entire history of the process (Astrom 1965) .
• a t : Action taken at time t, i.e., a t ∈ A t = W M , where W and M represent "Wait" and "Mammography," respectively.
• a : Observation space, which includes observations seen upon taking action a t . If a t = M, the decision maker can observe a positive mammogram (M+) or a negative mammogram (M−). If a t = W , the patient can make a self-detection (SD+) or no self-detection (SD−). That is, M = M+ M− and W = SD+ SD− .
• K a t o s : Observation probability, which represents the probability of making an observation o at time t when the action chosen is a and the true health state is s. Without loss of generality, we define the orderings between the observations as follows: SD− SD+ and M− M+. Observation probabilities are specified by the accuracy of the tests, and because these tests are imperfect, they provide only partial information about the true health state of the patient. In the medical literature, the accuracy of a test is typically measured by specificity-the proportion of cancer-free women who are identified as negative by the test-and sensitivity-the proportion of women with cancer who are identified as positive by the test. Let spec t M and spec t SD denote the specificity of mammography and self-detection at time t, respectively. Similarly, let sens t s M and sens t s SD denote the sensitivity of mammography and self-detection for true health Mammography decision-making diagram (BCa represents "breast cancer"). 
state s at time t, respectively. We define sensitivity as a function of the true health state s because, unlike specificity, sensitivity depends on the cancer stage (i.e., in situ or invasive). Then, the observation probabilities at time t are computed as follows:
• P a o t s s : Core state transition probability, i.e., the probability that the patient will be in state s ∈ S at time t + 1, given that she was in state s, took action a, and observed o at time t.
The decision process is presented in Figure 2 . The probability of a change in health state in the subsequent interval is the same for women who have a negative or a false-positive mammogram and those who do not receive a mammogram (Figure 2 ). That is, P M M− t s s = P W SD− t s s = P W SD+ t s s for all s s ∈ S and P M M+ t s 0 = P M M− t s 0 . Because information updates occur at discrete times, we update the corresponding information state at the end of this decision epoch. Note that a SD+ may change the optimal action taken in the future by increasing the belief about the cancer risk.
• b a o : Updated belief state, which captures the information on how transitions occur among the belief states. We define b a o = b a o s , where b a o s represents the probability of occupying state s ∈ S P O at time t + 1, given that the decision maker's belief about the patient's health state was b, action taken was a, and observation seen was o at time t. That is, b a o s = Pr t s b a o . Although b a o depends on time t, we drop this time index for the clarity of the notation.
Our modeling framework is different than the conventional POMDP models in two ways. First, the order of Operations Research 60(5), pp. 1019 -1034 , © 2012 events is different. In our model, at the beginning of each decision epoch t, an action is taken, an observation is seen and, depending on the outcome of the observation, the transition to a new state occurs (Figure 2 ). Whereas in a conventional POMDP model formulation (Smallwood and Sondik 1973) an action is taken, the transition occurs based on this action, and then an observation is seen, i.e., the observation is seen after the transition occurs. Second, in our model, unlike the conventional POMDP models, state transitions depend not only on the selected action but also on the observation seen. For example, upon experiencing a positive mammogram, if the woman has cancer, she starts treatment before a transition occurs and the decision process ends here (stopping condition). This modeling framework fits better, especially in diagnostic decisions, in which depending on the outcome of the observation, the follow-up procedure may change the state transitions (e.g., a biopsy might result in treatment). Note that when there is no stopping condition, it is possible to transform our POMDP into an equivalent classical POMDP (see the electronic companion for a proof). These differences change the beliefstate update equations as well as the optimality equations. We compute the updated belief state as follows:
When a = W o ∈ W or a = M o = M−, the computation of b a o is straightforward. When a = M and o = M+, if the patient is found to have cancer (s = 1 or s = 2) after a positive mammogram (M+), there is no update to the belief state because the treatment starts and the decision process ends. On the other hand, when a = M and o = M+, if the patient is found to be cancer free (s = 0), i.e., experiences a false-positive mammogram, then this patient continues to follow the decision process.
• R t s : Total expected postcancer QALYs accrued at time t when the patient is in one of the cancer states (s ∈ 1 2 ), detected by biopsy, and has started cancer treatment.
• r t s a o : Expected QALYs between time t and t + 1 when the patient's true health state is s, the action chosen is a, and the observation seen is o. The function r t s a o incorporates life expectancy between time t and t + 1 and disutilities associated with a mammogram that occurs in that time interval, estimation of which is explained in §3.2. Note that if the patient is in one of the cancer states, (s ∈ 1 2 ) and experiences a positive mammogram, then she is assigned a lump-sum reward (QALYs), R t s . That is, no QALYs are assigned over the next decision epoch upon experiencing a true positive mammogram, i.e., r t 1 M M+ = r t 2 M M+ = 0.
• r t s a : Expected QALYs between time t and t + 1 when the patient's true health state is s and the action chosen is a, which is computed by r t s a = o∈ a K a t o s · r t s a o .
• r T s : Total expected remaining QALYs at time T given that the patient is alive at time T and her true health state is s.
Optimality Equations
Let V * t and V * t b represent the maximum total expected QALYs the patient can attain when the current information state is ∈ S and the current belief state is b ∈ B S P O at time t, respectively. Then,
Also, let V a t b represent the maximum total expected QALYs the patient can attain upon taking action a when the current belief state is b ∈ B S P O at time t. Then,
where
Moving the functions that do not depend on s out of the summation over s ∈ S and noting that s ∈S P a o t · s s = 1 for all s ∈ S P O , a ∈ A, and o ∈ , we obtain
T −1 and, (3)
An Alternative Form for the Optimality Equations
In this section, we present an equivalent representation for the optimality equations that is used for developing solution algorithms and is easier to interpret. We start with the following lemma, which shows that the optimal value function is piecewise linear and convex, upon which the alternative representation is built. The proofs of all results in this section are presented in the electronic companion.
Lemma 1 (Smallwood and Sondik 1973) . The optimal value function V * t b is piecewise linear and convex for all t T , and hence can be expressed as the maximum of a finite number of linear functions. That is, We next present the optimality equations in terms of the -vectors.
Proposition 1. The optimal value function V * t b can be equivalently represented as follows.
Note that b a o depends on time t; however, we drop this time index for the clarity of the notation. The following lemma presents the explicit representation of the -vectors, upon which the solution algorithms are built. 
and
For our problem,
s can be intuitively interpreted as the maximum QALYs that a patient with belief state b can obtain when her true health state is s at time t.
We further structurally analyze this POMDP and present reasonable sufficiency conditions that ensure the existence Operations Research 60(5), pp. 1019-1034, © 2012 INFORMS of structured value functions and policies in the electronic companion. In particular, we first show that the sufficiency conditions used in previous POMDP models for the monotonicity of the optimal value function in belief vector b are not satisfied in our case, and provide new sufficiency conditions. Second, we show under certain assumptions that the optimal policy is of control-limit type. That is, if the optimal action for a relatively healthier (sicker) patient is Mammography (Wait), then the optimal action for a sicker (healthier) patient should also be Mammography (Wait). Unfortunately, the assumptions mentioned depend on the computed parameters from a previous iteration, and hence do not provide a way to predict a control-limit policy before that policy is actually computed. Nevertheless, we believe these results shed useful insights into the overall problem.
Model Inputs
In this section, we first present our sources of model inputs in §3.1, then describe selection of model inputs in §3.2, and finally in §3.3 we present models for estimating breast cancer risk, which is necessary to implement the POMDP model.
Sources of Model Inputs
Our primary source of model inputs is a validated microsimulation model of breast cancer epidemiology in the United States developed at the University of Wisconsin, Madison, which we refer to as the University of Wisconsin Breast Cancer Simulation (UWBCS). The UWBCS was developed as part of the Cancer Intervention and Surveillance Modeling Network (CISNET), a National Cancer Institute (NCI)-sponsored consortium focusing on statistical modeling of the impact of cancer control interventions and optimal cancer control planning (see www.cisnet.cancer.gov). Some of the CISNET breast cancer models, including the UWBCS, have been used to investigate population-based mammography-screening strategies , Mandelblatt et al. 2009 ). In fact, CISNET models, including the UWBCS, provided evidence for the recent USPSTF recommendations ( The UWBCS is a highly detailed simulation model designed to replicate breast cancer natural history, detection, treatment, and mortality rates in the U.S. population. The states of the UWBCS model include cancer-free, in situ, localized invasive, regional invasive, and distant invasive cancers. The model is able to replicate populationlevel U.S. cancer surveillance data by simulating the individual life histories of women aged 20 years or older in proportion to their prevalence in the U.S. population. The UWBCS is informed by NCI-provided inputs common to all CISNET models and calibrated to breast cancer incidence data reported by the NCI's Surveillance, Epidemiology, and End Results (SEER) program and breast cancer mortality data reported by National Center for Health Statistics using the acceptance sampling method. The model is further cross validated against the Wisconsin Cancer Reporting System (WCRS). Detailed descriptions of model design, assumptions, and validation have been published elsewhere ).
Selection of Input Parameters
Sources of model inputs are listed in Table 2 . We specify the age-specific core state transition probabilities representing the natural history of breast cancer and expected QALYs at each decision epoch (i.e., intermediate rewards) using the UWBCS model. We combine the localized, regional, and distant invasive cancer states in the UWBCS into a single invasive cancer state. To specify the transition probabilities that represent the natural history of breast cancer, we exclude screening from the simulation model and calculate the model predictions that represent individual life histories of over 22 million women. We specify the age-specific transition probability p ij as the proportion of transitions from state i that end up in state j. We validated that the POMDP model informed by these transition probabilities is able to reproduce the U.S. population under no screening scenario.
To specify the total expected QALYs before a cancer detection during each decision epoch, i.e., the intermediate rewards r t s W · and r t s M M− , we employ the half-cycle correction method (Sonnenberg and Beck 1993) using age-and state-specific mortality rates from the transition probabilities and disutility values of mammography. Specifically, to specify the total QALYs at the current decision epoch when the action taken is Wait, we assign 0.5 life years if the patient is alive in the current decision epoch, and 0.25 life years if the patient dies in the current decision epoch. That is, r t s W · = 0 5 * P (alive in the current decision epoch current health state is s + 0 25 * P (dies in the current decision epoch current health state is s . To specify the intermediate rewards when the action taken is Mammmography, we subtract the disutility values associated with a mammogram from the intermediate rewards gained when the action taken is Wait. That is, if we let du M o s denote the disutility associated with (Mandelblatt et al. 1992 ), (b) two weeks for a true positive mammogram (Velanovich 1995) , and (c) four weeks for a false-positive mammogram, because the literature reports that the disutility for a falsepositive mammogram is higher than that for a true-positive mammogram (Earle et al. 2000) . We assume that mammograms do not increase the future risk of cancer, because the ACS reports that this risk is minimal (ACS 2009). We specify the postcancer life expectancies-i.e., the lumpsum rewards R t s -using age-specific mortality rates for patients under cancer treatment from the SEER data (Jemal et al. 2009 ), based on the method described in Arias (2006) . We draw from the literature to specify sensitivity and specificity of exams (mammography, BSE, CBE), which generate the observation probability matrices. Specifically, we obtain age-specific sensitivity and specificity of mammography separately for in situ and invasive cancers from Kerlikowske et al. (2000) , sensitivity and specificity of CBE from Barton et al. (1999) , and sensitivity and specificity of BSE from Baxter (2001) (Table 3) . To specify the sensitivity and specificity of self-detection, we compute the weighted average of CBE and BSE sensitivity and specificity values by using the CBE and BSE proportions in the population reported by Elmore et al. (2005) and Messina et al. (2004) (Table 2 ). In the following section we describe how we estimate the risks of in situ and invasive cancer at age 40, which are necessary to implement the optimal screening strategy obtained by the POMDP model.
Risk Estimation Models
The estimated risks of in situ and invasive cancer are used to calculate the initial belief states at age 40. The risks at later ages can be calculated by using these initial belief states and screening history via the belief update Equation (1). There are several risk estimation models for in situ and invasive breast cancers that could be used for this purpose (see, for example, Reinier et al. 2007 , Claus et al. 2001 , Trentham-Dietz et al. 2000 . To find the risks at age 40, we use a modified version of the Gail model, which is a validated model for predicting breast cancer risk in individual patients in daily clinical practice, and the most commonly used risk estimation model in the medical community ).
The Gail model estimates the invasive breast cancer risk for an individual based on the following risk factors: current age, age at menarche, age at first live birth, number of first-degree relatives with breast cancer, number of previous biopsies, and presence of atypical findings on a biopsy. The initial Gail model was primarily based on a Caucasian population and provided the estimation for total risks of in situ and invasive risks. Later modifications to this model allowed applicability to African-American women and estimating the risk specifically for invasive breast cancer . To estimate the in situ cancer risk, Gail et al. (1999) proposed using the incidence ratio between in situ and invasive cancers. The modified version of the Gail model is available on the NCI's website (http://www.cancer.gov/bcrisktool/) and is used 20,000 to 30,000 times each month to quantify an individual woman's risk of breast cancer (Elmore and Fletcher 2006) .
Computational Experiments
We solve our POMDP model optimally using Monahan's algorithm (Monahan 1982 ) with Eagle's reduction (Eagle 1984 ) (see the electronic companion for the algorithm). We used an Intel Xeon 2.33 GHz processor with 16 GB RAM for our computational experiments. The computation time for solving the base case using our solution algorithm was 55.95 hours.
Optimal Screening Strategy
Figure 3 depicts the optimal screening strategy as a function of in situ and invasive breast cancer risks for various ages. In Figure 3 , the horizontal and vertical axes represent the probability (risk) of in situ and invasive cancer, respectively; therefore, the probability of being cancer free is equal to 1 minus these probabilities (e.g., if the risk of in situ cancer = 0 001 and the risk of invasive cancer = 0 003, then the probability of being cancer free = 1 − 0 001 −0 003 = 0 996). As shown in Figure 3 , there exists threshold risks of in situ and invasive cancers beyond which the optimal action is Mammography, as proven in Theorem 2 (electronic companion). In addition, the mammographyscreening threshold risk for invasive cancer is lower than that of the in situ cancer. In other words, the risk of invasive Optimal mammography-wait decisions for patients at different ages. cancer is more significant than the risk of in situ cancer in determining the mammography decision, as proven in Corollary 2 (electronic companion). Furthermore, the area for which the Wait action is optimal increases as the patient ages, i.e., the threshold risk for the Mammography action is higher in older women. Note that because the risk of breast cancer also increases with age, we cannot directly interpret this finding because older patients are less likely to be recommended for mammography. Instead, the mammography decision is determined by the trade-off between these two factors, as illustrated in the following case examples.
Case 1. We consider a 40-year-old white woman who has no personal or family history of breast cancer or a history of a previous biopsy, began menstruation at age 14, and her first birth was at age 23. Using the Gail model described in §3.3, we estimate this patient's current risks of in situ and invasive cancers as 0.1% and 0.2%, respectively. Based on our model, we find that the optimal action for this patient is to Wait, as opposed to the recommendations by some population-based guidelines (Figure 3) .
Case 2. We now consider a 50-year-old white woman who has the same risk factors as the woman in Case 1. We know that this patient did not have any prior mammograms. Using the Gail model and belief update equation in (1), we estimate this patient's current risks of in situ and invasive cancers as 0.6% and 0.7%, respectively. Based on our model, we find that the optimal action for this patient is to have a Mammmogram, as recommended by populationbased guidelines (Figure 3 ).
Our POMDP model could also be used to find the optimal screening intervals, depending on the outcome of the observations. For example, for the patient in Case 1, assuming that no self-detection occurs in the following years, her next mammography screening should be scheduled for age 42. Similarly, for the patient in Case 2, if the outcome of the mammogram at age 50 is negative and no self-detection occurs in the following years, her next mammography screening should be scheduled for age 53. Similarly, we can find the optimal screening intervals for all possible belief, action, and observation scenarios. Below, we provide two examples to illustrate how risk stratification affects screening recommendations and how screening intervals may change after years of negative mammograms.
Case 3. This example illustrates how risk stratification affects screening recommendations. Suppose we have a patient at age 40, whose in situ and invasive cancer risks are estimated as 0.0016 and 0.0035, respectively. Then, based on the optimal screening policy presented in Figure 3 , the optimal action for this patient is to undergo mammography at age 40. Assuming that the outcomes of this and the following mammograms are all negative and no self-detection occurs, this patient should undergo mammography exams at ages 40, 44, 48, 51, 55, 58, 62, 66, and 72 . The updated risks and the corresponding optimal actions for this patient are presented in Table 4 .
Case 4. This example illustrates how screening intervals may change after years of negative mammograms. Suppose the same patient in Case 3 undergoes annual mammography exams between ages 40-55 (including age 55), all of which turn out to be negative. Using the belief update equation (Equation (1)), we estimate her updated risk at age 56 as 0.25% for in situ cancer and 0.13% for invasive cancer. Then, our results show that the next mammogram should be scheduled for age 60. That is, the screening interval increases from 3 years to 5 years after 15 years of annual mammograms (see in Case 3 that if a woman is screened at age 55, the next screening should be scheduled for age 58). For this specific patient, the updated risks and the optimal actions are given in Table 5 . A woman's prior screening history may significantly influence the estimated risk of breast cancer (Elmore et al. 2005) , and in turn might change the optimal action. Figure 4 shows how estimated breast cancer risk changes under different screening scenarios. Specifically, we compare three scenarios: no screening, screening biennially after age 40, and screening biennially after age 50, assuming that each screening result was negative. To illustrate, consider two different patients who are both 55 years old with the same risk characteristics, but different screening histories: patient 1 has never had a screening mammogram; patient 2 had prior mammograms at ages 50, 52, and 54, all of which were negative. Then, as shown in Figure 4 , whereas patient 1 has a 2.6% total risk of breast cancer (1.4% invasive, 1.2% in situ), patient 2 has only 0.53% total risk (0.19% invasive, 0.34% in situ). Whereas the optimal action for patient 1 is to have a Mammogram, the optimal action for patient 2 is to Wait at the current time period. This suggests that incorporating personal history of screening into screening recommendations may reduce unnecessary mammograms and help make better screening decisions.
Actual Screening Policies vs. the Optimal Screening Strategy
In this section, we compare the performances of no screening and several actual population-based screening guidelines presented in Table 1 to our proposed optimal screening strategy. When the age to end screening is not specified by an actual screening policy, we set the ending age to either 74 or 79, because these are the commonly accepted ending ages (Mandelblatt et al. 2009 ). Specifically, we compare the total expected QALYs, the number of mammograms, the number of false positives, and the lifetime risk of developing undetected invasive cancer by each screening scenario for an average-risk and a high-risk patient at age 40. We define a high-risk patient as someone who has a family history of breast cancer. We estimate the cancer risks for average-and high-risk women using the risk estimation model described in §3.3. We assume that if the patient has a detected cancer at any time period, she is treated and kept under surveillance with annual mammograms until age 80, regardless of the policy adopted. Table 6 and identify efficient frontiers. In Table 6 , when calculating the expected number of mammograms and false positives, we assume that women with a personal history of breast cancer will have the same mortality rates with those women without any personal history, because very little is known about the mortality rates of such women. For an average-risk patient, the optimal screening strategy reduces the expected number of mammograms by more than 14, reduces the number of false-positive mammograms at least by half, and increases the total expected QALYs by at least 2.3 months, compared to annual screening between ages 50-79. Although the reductions in the expected number of mammograms and false positives are remarkable, the savings in total expected QALYs may appear to be nonsignificant. However, as Wright and Weinstein (1998) highlight, the gains of months in QALYs from screening are equivalent to gains of years from breast cancer treatment. Furthermore, these savings increase with increased risk.
There appears to be little benefit in screening women after age 74 in terms of the QALY gains. On the other hand, according to our model, screening women between 40-49, an age group where benefits of mammography are particularly controversial, does provide significant QALY gains, especially for high-risk women due to a longer life expectancy (Table 6 ).
In terms of lifetime risk of developing an undetected invasive cancer (an invasive cancer that is not detected by any mammograms during the woman's lifetime), aggres- sive screening policies with earlier starting ages (such as annual screening between 40 and 79) perform better than the other recommended policies, as expected. For many cases (including both average and high-risk women), the optimal screening strategy results in a lower lifetime risk of developing undetected invasive cancer than the various recommended screening policies. Although the optimal screening strategy leads to a higher lifetime risk of developing undetected invasive cancer than some of the aggressive screening policies (such as annual screening between 40 and 79), this difference is significantly smaller when compared to the difference between no screening and the optimal policy. Furthermore, the difference in lifetime risk of developing undetected invasive cancer does not necessarily imply the same magnitude of difference in life years, Figure 5 .
Societal trade-off representation of the screening policies reported in Table 6 . because (1) undetected invasive cancers do not always lead to mortality, and (2) deaths due to undetected invasive cancers at older ages might not make a significant difference in life years.
To assess how these differences in lifetime risk of developing undetected invasive cancers translate into life years, we calculated life years (in addition to QALYs) associated with annual screening between ages 40-79 (which results in the minimum lifetime undetected invasive cancer risk) and the optimal screening strategy. The difference in life years between the annual screening policy between ages 40-79 and the optimal screening strategy was very small for average-risk women (around 0.006 years, or equivalently 2 days). Furthermore, for high-risk women, the optimal screening strategy performed slightly better than the annual screening between ages 40-79 in terms of life years (40.432 versus 40.429). This is because the optimal screening strategy has the power to require biannual screening at times if needed, which might be useful, especially at younger ages. In fact, separate analyses showed that, for high-risk women, the optimal screening strategy asks for very aggressive (biannual) screening at younger ages Figure 6 .
Personal trade-off representation of the screening policies reported in Table 6 . (1) an existing cancer is detected, or (2) several sequential negative mammograms are observed, which significantly decreases the woman's risk of breast cancer. For example, for a 40-year-old high-risk woman, the optimal strategy prescribes four sequential mammograms until age 42 (at ages 40, 40.5, 41, and 41.5).
Another measure for screening efficiency would be the delay in cancer detection at early stages; however, our model does not include cancer stages and hence does not allow computation of such a statistic. To assess the robustness of the results presented in this section, we conduct sensitivity analyses on input parameters, which show that the results are sensitive to the disutilities associated with a mammogram and substantially robust against small changes in the accuracy of mammography (see the electronic companion).
Value of Self-Detection
To investigate the effect of self-detection in early diagnosis of breast cancer, we compare the total expected QALYs and number of mammograms obtained by the optimal screening Operations Research 60(5), pp. 1019-1034, © 2012 INFORMS strategy for various self-detection scenarios. We find that for a 40-year-old average-risk patient, the total expected QALYs is 40.01 and the total expected number of mammograms is 22.37 when no self-detection is available, whereas when self-detection is available the total expected QALYs increases to 40.19 and the total expected number of mammograms decreases to 14.04. That is, for a 40-year-old average-risk patient, the optimal screening strategy with self-detection results in at least two months more QALYs and requires at least eight fewer mammograms than that without self-detection. Our results show that self-detection is beneficial for reducing the expected number of mammograms and increasing the life savings.
Conclusions
Current population-based mammography screening guidelines consider only age in screening recommendations, whereas age is just one of the several important risk factors for breast cancer. Understanding that women at the same age groups do not have uniform breast cancer risks suggests that personalized screening strategies may be more beneficial in increasing life savings in high-risk women while decreasing unnecessary complications in lowrisk women (IOM 2005) . Individualizing mammographyscreening decisions based on personal risk characteristics of women is identified as crucial to improve breast cancer diagnosis by numerous researchers and several health organizations. On the other hand, no structured protocol exists to individualize this process. In this study, we develop an analytic model to personalize mammography screening decisions based on a woman's personal risk characteristics. This is consistent with the notion of "personalized medicine," noted to be the future of American medicine (Liebman 2007) .
We formulate this complex decision process as a POMDP, structurally analyze this POMDP, and solve it optimally. Our results show that, as hypothesized, age is not the only significant factor in determining the optimal mammography decisions. Specifically, we show that for some subgroups of women, their optimal screening decisions might be different than those recommended by several population-based guidelines. Our results also suggest that the mammography-screening threshold risk changes with age, being lower in younger women and higher in older women. This is consistent with the knowledge that older women are more likely to suffer from other comorbidities; hence, further invasive tests are often less beneficial for these women. On the other hand, although one would expect that older women need to be screened less aggressively than younger women, we find that this is not always the case, as demonstrated by our case examples. Although this finding appears counterintuitive, because breast cancer risk is also higher in older women, mammography decisions should be determined considering this trade-off. We show that, under this trade-off, screening is less beneficial for most women over age 74 and provides significant QALY gains, especially for the high-risk women in the controversial age group 40-49.
In addition, we show that our personalized screening strategies increase the savings in QALYs and significantly decrease the expected number of mammograms compared with the population-based screening guidelines. Our model might help reduce the number of unnecessary mammograms, which can cause harm and account for approximately $100 million in overspending per year in the United States (IOM 2005) .
In line with the previous research, our sensitivity analyses demonstrate that the model conclusions are sensitive to the disutility values associated with a mammogram, which should be determined based on personal assessments of women in designing a personalized screening program. Furthermore, we show that self-detection (a combination of BSE and CBE) is useful in increasing the total expected QALYs while reducing the expected number of mammograms, which is consistent with the ACS guidelines that suggest optional BSE and recommend annual CBE for women over age 40.
To individualize the mammography-screening process, we propose a statistic, i.e., the belief state, that can capture several possible risk factors. From a clinical standpoint, this new statistic and the results presented in this study might be useful for communication between the radiologist, patient, and referring physician. Our findings may in turn facilitate shared decision making, decision making within a patient-clinician partnership, which is especially recommended for complex decisions such as mammography screening (Sheridan et al. 2004) .
One of the key features of the personalized optimal mammography-screening strategy proposed in this study is that it considers not only personal risk characteristics, but also the personal history of screening when making recommendations for mammography decisions. Specifically, we illustrate how this extra piece of information might change the optimal decisions and help make better screening decisions. Whereas population-based guidelines for some other cancers such as prostate or colorectal consider the prior screening history, none of the existing breast cancer population-based guidelines currently do.
As noted by the 2005 IOM report, "individual screening strategies are essential to improving the early detection of breast cancer, and risk assessment is an essential step in the development of individualized screening strategies" (IOM 2005, p. 141) . To date, the Gail model is the most popular and reliable breast cancer risk assessment tool. However, the Gail model has some limitations. For example, it does not incorporate some genetic risk factors into the assessment. It is, nonetheless, the most commonly used model among physicians to estimate the individualized risk because there are no better models. Therefore, IOM encourages future researchers to focus on developing accurate risk assessment tools to be used as inputs in personalized breast cancer screening models (IOM 2005).
Our study has limitations. First, our results, informed by unrevealed inputs (available from authors upon request), are based on point estimates for the model parameters. Although we present sensitivity analyses for disutility and mammography accuracy parameters (see the electronic companion), we do not provide a sensitivity analysis for the transition probabilities. Second, our POMDP model does not explicitly consider the dynamic risk factors that may change after age 40 (such as breast density, BMI, or a change in family history). For example, if a 50-year-old woman learns that a first-degree family member has breast cancer, which was unknown to her before, then the belief update does not reflect such a change because it was not known a priori and hence not considered in the transition probability estimations. One possible approach to ameliorate the effects of this limitation would be to reset the estimated risk at the time of change (i.e., recalculate the risk at age 50 considering that a family member has breast cancer in our example). In this case, the effects of negative screening results between age 40 and age at which the change occurs (age 50 in our example) would be lost. Because a negative screening always decreases the estimated risk of cancer, our reestimated risk at the time of change (age 50 in our example) would be an overestimation. Therefore, our policy recommendation would be more conservative.
There are several future research directions. One is to explore the effect of adherence and participation of women to the recommended policies. The literature reports that the participation rate is low, with less than 10% of women reporting to undergo annual mammograms over a period of 9-10 years (Partin et al. 2005) . In addition, we may incorporate the economical costs associated with mammography and follow-up tests into the decision problem to gain insight about the optimal strategy from the society's perspective. Lastly, we may consider the risk behavior of the decision maker and investigate how different risk attitudes change the mammography decision process. All these analyses require different model formulations and are left for future work.
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ONLINE APPENDIX
A. Transforming our POMDP framework into an equivalent conventional POMDP
In this appendix, we show that when there is no stopping, our POMDP model could be transformed into an equivalent conventional POMDP model. We drop time index t from probability and reward functions for simplicity, and do the calculations accordingly.
In conventional POMDP formulation, the optimal value function is given by:
Since an observation is seen after a transition occurs in conventional POMDP models, the observation probability only depends on the future state s and action a, but not the current state s, i.e. P r(o|s , a) = P r(o|s, s , a).
Thus, the optimality equation in conventional POMDP models can be represented equally as follows:
On the other hand, the optimality equation that emerges from our modeling approach (when there is no stopping condition) is given as follows:
We will show that there is a one to one mapping between equations (12) and (13).
We first investigate the relationship between P r(o|s, a, s ) and P r(o|s, a).
P r(o|s, s , a) = P r(s , s, a, o) P r(s , a, s)
= P r(s |s, a, o)P r(o|s, a)P r(s, a) P r(s |s, a)P r(s, a)
= P r(s |s, a, o)P r(o|s, a) P r(s |s, a) Substituting (17) into (12), we obtain:
Canceling P r(s |s, a) in the nominator and denominator, we obtain:
Using ι(b, a, o) definition given in (14), we obtain:
which is equal to (13).
In addition, unlike the conventional POMDP models, state transition probabilities depend on the observation o in our POMDP model. However, P r(s |s, a) can be evaluated by computing P r(s |s, a) = o∈O P r(s , o|s, a) = o∈O P r(s |s, a, o)P r(o|s, a).
Therefore, when no stopping action exists, there is a one-to-one mapping between our modeling and conventional POMDP modeling approaches.
B. Proofs of the Analytical Results
Proof of Proposition 1. We first find the equivalent representation of V * (1) into (5), we get
In (23), because s∈S P O b(s)K a t+1 (o|s) does not depend on s and k, we can move it out of the sum and max operators. Also, changing the order of summation and substituting ι(b, a, o) from (7), we obtain the following:
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Now, we substitute the value of
Substituting the value of (24) into (25), we obtain
where (26) follows from changing the order of summation and rearranging the terms, (27) follows from canceling the terms in the nominator and denominator, and (28) follows from simple algebra. Again from (3), we know that
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from which the result follows.
Proof of Lemma 2. This lemma directly follows from Lemma 1 and Proposition 1.
C. Structural Properties
In this appendix, we derive several structural properties of the POMDP model formulated in §2. Specifically, we present reasonable sufficiency conditions that ensure the existence of structured value functions and policies. We first provide some definitions that are used in proving our main results.
Definition 1. a) (Whitt 1979) . Given two probability mass functions x and x with dimension |X|,
we say x is stochastically smaller than x , denoted by x ≤ s x , if
b) (Ferguson 1967) . Given two probability mass functions x and x with the same dimension, we say x is smaller than x in the sense of monotone likelihood ratio (MLR) partial order, denoted by x ≤ r x , if
c) (Karlin 1968) . An m × m matrix P = [P (j|i)] is Totally Positive of order 2 (TP2) if P (j|i)P (k|s) ≥ P (k|i)P (j|s) for any s, k, i, j ∈ {1, 2, ...m} whenever s ≥ i, k ≥ j.
Stochastically smaller or MLR dominated belief states represent patients with better health conditions. Throughout this appendix, a "better belief" implies that such a patient has a higher probability of occupying better health states. Before proving Proposition 2, which shows that the optimal value function is monotone in belief vector b when the patient is recommended to Wait, we provide three lemmas and a definition that are used in this proof. Lemma 3. a) (Rosenfield 1976) . Let x and x be two probability mass functions with the same dimen-
b) (Karlin 1960) . Let x and x be two probability mass functions with the same dimension |X|. Then,
x ≤ s x if and only if i∈X x(i)f (i) ≥ i∈X x (i)f (i) for every f : X → R nonincreasing on X.
Definition 2. (Horn 1990) . Let P = [p ij ] and Q = [q ij ] be m × n matrices. The Hadamard product of P and Q is defined by
Lemma 4. Let P and Q be m × m TP2 matrices and x and x be two probability mass functions with dimension m such that x ≤ r x . Then x(P ⊗ Q) ≤ r x (P ⊗ Q).
Proof of Lemma 4.
Because both P and Q are TP2, p i j p ij ≥ p i j p ij , and q i j q ij ≥ q i j q ij whenever i ≥ i , and j ≥ j . Then, p i j q i j p ij q ij ≥ p i j q i j p ij q ij . Thus, P ⊗ Q is TP2. The result then follows from Theorem 2.4 in Karlin and Rinott (1980) , which implies that if a matrix A is TP2 and x ≤ r x , then xA ≤ r x A.
The final lemma (Lemma 5) that we need presents conditions under which the belief state update preserves the MLR ordering for different belief states and observations. In this lemma, we assume that the observation and transition probability matrices are TP2, which intuitively implies that as the patient gets sicker, there is a greater chance of making a positive observation (M + or SD+) and the patient is more likely to move to sicker health states, respectively. Lemma 5(a) implies that if the current belief on the states for patient A is better than that for patient B, regardless of the action taken and the observation seen (as long as they are the same for both patients), the updated belief for patient A will be better than that for patient B. Lemma 5(b), on the other hand, implies that if the current belief for two identical patients C and D are the same, then upon taking a Wait action, if patient C makes no-self detection and patient D makes a self-detection, the updated belief for patient C will be better. Throughout the remainder of this appendix, we define the observation probability matrix as
, where s represents the row and o represents the column and P 
and P 
). Writing out this expression explicitly, we obtain
Dividing both sides by
and B is TP2, it is easy to see that
is also TP2. Then, since the product of TP2 matrices is TP2, K W t 3×2
(B ⊗ Z t ) is TP2 as well. That means,
The following reasonable assumption is made throughout the remainder of this appendix.
2 ) for any a 1 , a 2 ∈ A t , and o 1 ∈ Θ a 1 , o 2 ∈ Θ a 2 for all t < T , and r T (s 1 ) ≥ r T (s 2 ). That is, as the patient gets sicker, the total expected QALYs over the next decision epoch does not increase.
In Proposition 2, we consider the case in which the transition probability matrix P 
Although the MLR assumption on belief states and TP2 assumption on observation and transition probabilities are typically sufficient to prove the monotonicity of the value function V * t (b) in belief states b in conventional POMDP models (Lovejoy 1987 , Rieder and Wagner 1991 , Krishnamurthy and Wahlberg 2009 ), these assumptions are not sufficient for our problem, as noted in the following remark.
, and
be TP2 for every t ≤
might not hold as demonstrated by the following counter example, which uses the instances of input data described in §3.2. 
Then, combining (42) and (43), we obtain
To have a generic representation of any α-vector, we now define z t (s, a, o) such that α (8) and (9) in Lemma 2. That is,
Since there is only one α-vector at time T, α T (s) = r T (s), the assertion holds for t=T by (As1 ).
Assume now that the assertion holds for n = t + 1, ..., T . Suppose α * (b 1 ) t is generated by the action
is generated by the action a 2 . We would like to come up with a relationship between z t (s 1 , a 1 , o 1 ) and z t (s 2 , a 2 , o 2 ). Before doing so, let's look at an example. Suppose
(2)
where (46) follows from (44) and (47) follows from the induction assumption. Combining (48) with
Comparing all possible cases in a similar manner, we obtain: and the induction assumption when a 1 = M , o 1 = M +, and when a 2 ∈ A and the corresponding o 2 ∈ {SD−, M −}. In Corollary 1, we show that any optimizing α-vector is nonincreasing in s ∈ S P O . (s ) ≥ R t (1) ≥ R t (2) for any a ∈ A, and o ∈ Θ a ,
c) r t (1, a, o) + (1) ≥ R t (2) for any a = W, o ∈ Θ W , or a = M, o=M-,
d) R t (1) ≥ r t (2, a, o) + P 
Then V * t (b) ≥ V * t (b ) whenever b ≤ s b ∈ B(S P O ) for any t = 1, 2, ..., T .
In Condition (50), P (a,o) t (j|i) = 0 whenever j < i means that the health condition of a cancer patient cannot improve on its own. The other two inequalities in this condition intuitively means that as the in the second line on the right hand side. After making these changes, we obtain the following: 
Figure 7
Change in threshold cancer risks for mammography decisions at different disutility values.
are more sensitive to the disutility associated with a false-positive mammogram than the disutility associated with a true positive mammogram (Table 7) . This is because the lifetime likelihood that an average-risk 40-year-old woman will experience a negative mammogram is significantly higher than the likelihood of experiencing a false-positive mammogram, which is significantly higher than the likelihood of experiencing a true positive mammogram. As seen in Table 7 , as the disutilities associated with a mammogram increase, the total expected QALYs and expected number of mammograms decrease. In Figure 7 , the vertical axis represents the total threshold risk for for the Mammography action, which is defined as the maximum of the sum of the insitu and invasive cancer risks, for which the Wait action is optimal. That is, total threshold risk = max b 1 (1) + b 2 (2) a * (b 1 ) = W, a * (b 2 ) = W . As the disutility of the exams increases (decreases), the total threshold risk for the Mammography action increases (decreases); therefore, the patients are less (more) likely to be recommended for mammography.
We present the sensitivity of the POMDP model across changing specificity (true negative rate) and sensitivity values (true positive rate) of mammography at all age groups in Figure 8 . As expected, the results are sensitive to the specificity of mammography. As the specificity of mammography increases (decreases), the total threshold risk for the Mammography action decreases (increases). That is, as the false-positive rate of mammography decreases, since the potential harms of mammography and unnecessary follow-up procedures also decrease, patients can be screened more aggressively. On the other hand, the results are substantially robust against relatively small changes in the sensitivity of mammography. This may appear counterintuitive; however, this is because the probability of experiencing a 
Figure 8
Change in cancer risks for mammography decisions for varying mammography accuracies.
false negative mammogram is significantly smaller than the probability of experiencing a false-positive mammogram.
Note that we assume risk neutrality in this study, which is a standard assumption for medical intervention modeling. On the other hand, although performing a sensitivity analysis on different risk attitudes is beyond the scope of this paper, we acknowledge that incorporating risk attitudes into the decision process might have a significant effect on the optimal screening policy.
